The combination of camrelizumab with albumin-bound paclitaxel and cisplatin may enhance long-term survival in patient[ (2, 17).In this retrospective study, we evaluated 225 patients with cT3–cT4a ESCC, who received one to four cycles of camrelizumab plus albumin-bound paclitaxel/cisplatin followed by radical surgery. This evidence concerns the gene ALB and esophageal squamous cell carcinoma.